

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Viksø-Nielsen et al. Confirmation No: 2808

Serial No.: 10/561,671 Group Art Unit: 1651

Filed: December 22, 2005 Examiner: TBA

For: Starch Process

INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(b)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is enclosed. It is respectfully requested that these references be considered by the USPTO in its examination of the above-identified application and be made of record therein.

Additional Information Concerning U.S. Application Publication No. 2005/0042737

U.S. Application No. 10/877,007 ("the 007 application"), which published as No. 2005/0042737, is related to the instant application. During the prosecution of the 007 application, certain claims were rejected as being anticipated by Shi et al. (U.S. Patent No. 6,054,302) and one claim was rejected as being obvious over Callen et al. (U.S. Application Publication No. 2003/0125534) and Shi et al. The Office is respectfully requested to consider the 007 application and its prosecution history in its examination of the above-identified application.

This IDS is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,

Date: August 16, 2007

/Elias Lambiris, Reg. # 33728/
Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097